Alicia Grande - Dec 8, 2023 Form 4 Insider Report for CATALYST PHARMACEUTICALS, INC. (CPRX)

Role
VP, Treasurer and CFO
Signature
/s/ Alicia Grande
Stock symbol
CPRX
Transactions as of
Dec 8, 2023
Transactions value $
-$1,283,780
Form type
4
Date filed
12/12/2023, 05:00 PM
Previous filing
Mar 30, 2023
Next filing
Dec 29, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CPRX Common stock, par value $0.001 per share Options Exercise $45.2K +40K +79.12% $1.13* 90.6K Dec 8, 2023 Direct
transaction CPRX Common Stock, par value $0.001 per share Sale -$285K -20K -22.09% $14.25 70.6K Dec 8, 2023 Direct F1
transaction CPRX Common Stock, par value $0.001 per share Sale -$286K -20K -28.35% $14.30 50.6K Dec 8, 2023 Direct F1
transaction CPRX Common Stock, par value $0.001 per share Options Exercise $67.8K +60K +118.68% $1.13* 111K Dec 11, 2023 Direct
transaction CPRX Common Stock, par value $0.001 per share Sale -$412K -30K -27.14% $13.74 80.6K Dec 11, 2023 Direct F1, F2
transaction CPRX Common Stock, par value $0.001 per share Sale -$414K -30K -37.24% $13.79 50.6K Dec 11, 2023 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CPRX Options to purchase common stock Options Exercise $0 -40K -3.09% $0.00 1.26M Dec 8, 2023 Common Stock 40K $1.13 Direct F4
transaction CPRX Options to purchase common stock Options Exercise $0 -60K -4.78% $0.00 1.2M Dec 11, 2023 Common Stock 60K $1.13 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Ms. Grande sold the shares on the open market, for personal reasons, and to fund the exercise price and tax withholding of the exercise of the stock option, and not as a a result of any disagreement with the Company.
F2 Represents a weighted average price for the shares sold. Shares were sold in various lots ranging from $13.74 to $13.745 per share.
F3 Represents a weighted average price for the shares sold. Shares were sold in various lots ranging from $13.78 to $13.79 per share.
F4 Options vested in three annual tranches beginning on January 3, 2018.